AI assistant
Median Technologies — Capital/Financing Update 2015
Jan 26, 2015
1514_rns_2015-01-26_2385892a-d8a3-4972-8e12-c4dc8ede837a.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Press release
MEDIAN Technologies' semiannual balance sheet for the liquidity contract with AUREL BGC
Sophia Antipolis, France – January 26, 2015 – On December 31, 2014, the liquidity contract account attributed by MEDIAN Technologies to AUREL BGC registered the following balances:
- €58,419.48
- 19,529 shares
As a reminder, the liquidity contract account registered the following balances on June 30, 2014:
- €53,713.68
- 19,837 shares
About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world's largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon
to develop new imaging technologies, and to address the patient care market.
Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia. MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market. (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: www.mediantechnologies.com
"We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients."
Contacts
| MEDIAN Technologies | Press | Investors |
|---|---|---|
| Fredrik Brag, CEO | ALIZE RP | ACTIFIN |
| +33 4 92 90 65 82 | Caroline Carmagnol | Ghislaine Gasparetto |
| [email protected] | Sophie Colin | [email protected] |
| + 33 1 44 54 36 66 | +33 1 56 88 11 11 | |
| [email protected] |